Overview

The AI‑driven Mid‑Cap Movers strategy added Amneal Pharmaceuticals (NASDAQ: AMRX) on 1 June 2026; the stock has risen 66.74 % since that pick date, making it one of the top performers highlighted in the article.

Q3 2026 Financial Results

On 30 October 2026 Amneal reported third‑quarter adjusted earnings per share of $0.30, surpassing the consensus estimate by 30.4 %. Revenue reached $796 million, a 10 % year‑over‑year increase and 5 % above the company’s own forecast.

FDA‑Related Catalysts

Earlier in the quarter the U.S. Food and Drug Administration removed a prior safety warning on estradiol patches, prompting a marked rise in demand for Amneal’s estrogen products. The company responded by investing in new equipment, adding a dedicated production line and pursuing third‑party supply partnerships. In the same period the FDA approved two Amneal denosumab biosimilars for the U.S. market, expanding the firm’s product portfolio.

Valuation and Operating Metrics

At the time of the AI pick the model flagged a PEG ratio of 0.35; the current PEG has compressed to 0.01, indicating the market may still be undervaluing earnings growth. Gross margin stands at 39.8 % and operating margin at 15.9 %. Free cash flow over the trailing twelve months totals $83 million. The stock trades at 99.2 % of its 52‑week high and carries a price‑to‑earnings multiple of 47.6.

Financial Health Scores

InvestingPro’s proprietary Financial Health score rates Amneal at 3.27 out of 5 (Great), with a momentum sub‑score of 4.6 out of 5 and a profitability sub‑score of 4.1 out of 5.

Mid‑Cap Movers Strategy Track Record

Since its launch in November 2023 the equal‑weighted Mid‑Cap Movers strategy has delivered a total return of 115.17 %, outperforming the S&P MidCap 400 by 61.37 % over the same period. The article also lists other AI picks and their returns: Everforth (+117.4 % since 1 July 2026), Delek US Holdings (+96.2 % since 1 March 2026), Consensus Cloud Solutions (+74.8 % since 1 February 2026), CVR Energy (+64.4 % since 1 August 2026), HF Sinclair (+63.4 % since 1 June 2026) and Bausch Health (+45.1 % since 1 May 2026).

AI Model Methodology

At the beginning of each month the proprietary AI system evaluates thousands of global equities using more than 15 years of financial data across over 150 quantitative models, selecting up to 20 high‑conviction stocks per strategy. Strategies are rebalanced monthly, with equal weighting applied to all selected stocks, providing a transparent benchmark for performance evaluation.

Subscription Information

InvestingPro members receive monthly AI‑generated pick lists for less than INR 260 per month; the November list, which includes Amneal, is available to subscribers via the provided links.

Disclaimers

These are real‑world numbers recorded since the official launch of the AI models in November 2023.

Past performance does not guarantee future results.